Search the Newsreel

Price to book forward of MediciNova, Inc. – NASDAQ:MNOV

This article displays the "Price to book forward" for MediciNova, Inc. (NASDAQ: MNOV) on TradingView. It provides financial data for the company, accessible through various features on the platform. The main content shows the period, value, and change metrics for this financial indicator.

Vanguard Capital Management (INO) discloses 5.05% beneficial stake in Inovio stock

Vanguard Capital Management has disclosed a 5.05% beneficial stake in Inovio Pharmaceuticals Inc. (INO), totaling 4,161,566 shares, as reported in a Schedule 13G SEC filing. Vanguard holds sole voting power over 511,004 shares and sole dispositive power over all 4,161,566 shares. This filing indicates …

Inovio Pharmaceuticals Secures $18.3 Million Stock-and-Warrant Offering With Piper Sandler

Inovio Pharmaceuticals has entered an underwriting agreement with Piper Sandler for a public offering valued at approximately $18.3 million. The offering includes 21,052,632 shares of common stock and warrants to purchase up to 42,105,264 additional shares, priced at $0.95 per share and warrant. The …

Form 424B5 Inovio Pharmaceuticals Inc For: 30 July By Investing.com

The article reports on the filing of Form 424B5 by Inovio Pharmaceuticals Inc. on July 30th. It is a brief update from Investing.com, likely concerning a securities registration or prospectus related to the company. The article also provides various market data unrelated to Inovio …

Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors

Inovio Pharmaceuticals Inc. (INO) stock dropped significantly by 36.92% on Thursday, closing at $0.66. This underperformance occurred despite a positive trading session for the broader market, with the NASDAQ Composite Index and Dow Jones Industrial Average both showing gains. The stock's decline ended a …

Inovio raises USD 20m ahead of make-or-break FDA decision on INO-3107

Inovio Pharmaceuticals has raised $20 million through an underwritten public offering as it anticipates a crucial FDA decision on its lead asset, INO-3107. The financing, which included shares and warrants, comes amidst a declining stock price and aims to extend the company's cash runway …

MediciNova Inc (MNOV) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for MediciNova Inc (MNOV), detailing its volatility, financial risk, and investment risk. The company's risk assessment score is 2.39, ranking 215 out of 385 in the Biotechnology & Medical Research industry, with a beta of 0.63 indicating less …

Medicinova Inc (MNOV) Edges Higher on Modest Volume, Testing Key Resistance - Donchian Channel

Inovio announces proposed public offering of stock and warrants By Investing.com

INOVIO Pharmaceuticals Inc. announced its plan for an underwritten public offering of common stock and accompanying warrants. The company will also grant the underwriter a 30-day option to purchase additional shares and warrants. The offering is subject to market conditions and there is no …

Inovio Offering Expected to Close Around July 31 >INO

The article states that Inovio's offering is anticipated to close around July 31.

INOVIO Announces Pricing of $20.0 Million Public Offering

INOVIO Pharmaceuticals, Inc. announced the pricing of a public offering for $20.0 million, consisting of common stock and accompanying warrants. The offering includes 21,052,632 shares of common stock and warrants to purchase up to 42,105,264 shares, priced at $0.95 per share and warrant. The …

INOVIO Pharmaceuticals Prices Public Offering of Common Stock

INOVIO Pharmaceuticals announced the pricing of a public offering of 21,052,632 shares of common stock and accompanying warrants at $0.95 per share, aiming to raise approximately $20 million. Piper Sandler is the sole manager for the offering, which includes an option for the underwriter …

INOVIO Plans Stock and Warrant Sale, Size and Terms Unclear

INOVIO announced its intention to conduct an underwritten public offering of common stock and accompanying warrants or pre-funded warrants. The proposed offering is subject to market conditions, and its completion, actual size, or terms are not yet assured, with Piper Sandler acting as the …

Inovalis REIT Stock Slides as Investors Assess Asset Sales, European Property Risks and Its Strategic Reset

MNOV Q1 2026 Earnings: EPS Beat Driven by Reduced Operating Costs, Stock Declines 3% - EPS Miss Report

MediciNova Inc (MNOV) Financial Health: Profitability & Balance Sheet Analysis

MediciNova Inc (MNOV) has a current financial score of 7.37, ranking 126 out of 385 in the Biotechnology & Medical Research industry, indicating robust financial status but low operating efficiency. The analysis from TradingKey outlines several financial dimensions including Quality of Earnings (8.20), Operational …

MediciNova Inc (MNOV) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of MediciNova Inc (MNOV), focusing on its stock price momentum, support and resistance levels, and various technical indicators and moving averages. The current price momentum score is 3.44, suggesting suitability for range-bound swing trading between $1.24 and $1.45. …

MediciNova Inc (MNOV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article concerns MediciNova Inc (MNOV) revenue breakdown by business segments and regional contributions. However, it states that the relevant data for FY2025, FY2025Q3, FY2025Q2, and FY2024 has not yet been disclosed by the company, making the provided regional breakdown effectively empty.

MediciNova, Inc. Revenue Breakdown – NASDAQ:MNOV

The article concerns MediciNova Inc (MNOV) revenue breakdown by business segments and regional contributions. However, it states that the relevant data for FY2025, FY2025Q3, FY2025Q2, and FY2024 has not yet been disclosed by the company, making the provided regional breakdown effectively empty.

MediciNova Inc (MNOV) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of MediciNova Inc (MNOV)'s dividend and stock split history, noting that the company has distributed a total of $0.00 in dividends over the past five years. It presents real-time stock data including the current price, market cap, and a …

MediciNova Inc (MNOV) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of MediciNova Inc (MNOV), listing its major shareholders, their proportional holdings, and the types of shareholders invested in the company. It also provides institutional shareholding trends over several quarters and recent shareholder activity, along with related ETF information.

Inovio Pharmaceuticals Inc (INO) Risk Assessment: Volatility, Financial Risk & Investment Risk

MediciNova, Inc. (NASDAQ:MNOV) Given Consensus Rating of "Moderate Buy" by Analysts

MediciNova, Inc. (NASDAQ:MNOV) has received a "Moderate Buy" consensus rating from six analysts, with an average 1-year price target of $8.33, significantly higher than its current trading price of $1.32. The company recently reported a smaller-than-expected quarterly loss of $0.05 per share, surpassing estimates, …

MediciNova Inc MNOV Income Statement

This page provides the quarterly and annual income statements for MediciNova Inc (MNOV), detailing financial performance metrics such as total revenue, operating expenses, R&D expenses, operating profit, and net income. It allows users to gain insights into the company's operational efficiency and profitability over …

Inovio Pharmaceuticals Inc (INO) Institutional Confidence

Inovio Pharmaceuticals Inc (INO) currently holds an institutional shareholding score of 3.00, placing it 192nd in the Biotechnology & Medical Research industry. Institutional ownership stands at 40.31%, showing a quarter-over-quarter increase of 9.34%. James Simons is identified as the largest institutional shareholder, holding 0.93% …

Inovio Pharmaceuticals Inc (INO) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Inovio Pharmaceuticals Inc (INO), listing major institutional shareholders like Fidelity Management & Research Company LLC, Janus Henderson Investors, and Vanguard Capital Management, LLC. It also breaks down shareholder types, showing investment advisors and hedge funds as significant …

Inovio Pharmaceuticals Inc (INO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Inovio Pharmaceuticals Inc (INO), focusing on business segments and regional contributions. It notes that relevant data for a detailed breakdown has not yet been disclosed by the company. However, it indicates a reported revenue of $65.34K from …

INO|Inovio Pharmaceuticals Inc|Price:0.980|Chg%:-0.041

This article provides a detailed financial overview of Inovio Pharmaceuticals Inc. (INO), including its stock performance, earnings estimates, and historical income statement, balance sheet, and cash flow data. It presents quarterly and annual financial indicators like EPS, revenue, net profit, and various ratios, along …

MediciNova Inc (MNOV) Institutional Confidence

MediciNova Inc's institutional confidence score is 3.00, placing it 192nd within the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 12.50%, a 42.46% decrease quarter-over-quarter. James Simons is the largest institutional shareholder, holding 0.39% of shares outstanding.

Enterprise value to EBIT forward of MediciNova, Inc. – NASDAQ:MNOV

This article from TradingView provides a financial snapshot of MediciNova, Inc. (NASDAQ: MNOV), focusing on its enterprise value to EBIT forward. It indicates that the market was closed at the time of the view and there were no trades. The article is part of …

MNOV|MediciNova Inc|Price:1.320|Chg%:+0.010

MediciNova Inc (MNOV) has a relatively healthy financial foundation and high growth potential, with its valuation considered fairly valued within the Biotechnology & Medical Research industry. Analysts predominantly rate the stock as "Buy," with a target price indicating significant upside. The company is in …

MediciNova Inc (MNOV) Valuation: PE, PB & Fair Value Analysis

MediciNova Inc (MNOV) has a current valuation score of 7.33, placing it 248th out of 386 in the Biotechnology & Medical Research industry. The company's P/E ratio is -5.53, which is a decline from its recent high but an increase from its recent low. …

Medicinova Inc (MNOV) Edges Higher in Low-Volume Trading, Holds Near Key Support - Fast Moving Stocks

Price to sales forward of MediciNova, Inc. – NASDAQ:MNOV

This article provides the "Price to sales forward" data for MediciNova, Inc. (NASDAQ: MNOV), as presented on TradingView. It appears to be a financial data snippet, showing the value and change percentage for this specific metric over a certain period.

MediciNova stock trades steady as investors weigh recent losses and pipeline progress

MediciNova (MNOV) stock continues to draw investor attention due to its late-stage neurology pipeline, despite an accumulated deficit of $540.8 million. The company reported a narrowed net loss of $19.0 million in 2024, down from $22.7 million in 2023, attributed to reduced operating expenses, …

What's Going On With Inovalis Real Estate Investment Trust Stock Wednesday?